Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.

United Therapeutics Corp. announced Feb. 4. that it will start a trial in mid-2025 with six patients who have end-stage renal disease. These patients, who have been on dialysis for at least six months ...

Austin patients are among the first in the country to have access to a new blood test capable of screening for colorectal ...

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market ...

Nuance Audio showcased its glasses with built-in hearing aids at CES 2025. Now that the product is FDA-approved, it will be available in the US in the coming months.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Susan Krause of Rosemount alleges New Jersey-based Integra LifeSciences pressured her to lie to regulators. Integra says ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...